Assignee
ADS THERAPEUTICS LLC
US·9 granted patents·6 pending applications·28 citations·filing 2017–2024
Top patents by PatentIndex Score
15 records- 0197US11191751B1Topical ophthalmological atropine free base compositionsADS THERAPEUTICS LLC·Filed 2021·Granted Dec 7, 2021·17 cites·12 claims
- 0294US12491183B2Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularizationADS THERAPEUTICS LLC·Filed 2024·Granted Dec 9, 2025·1 cites·13 claims
- 0392US12070501B1Topical ophthalmological compositionsADS THERAPEUTICS LLC·Filed 2022·Granted Aug 27, 2024·2 cites·15 claims
- 0490US12485177B2Topical ophthalmological compositionsADS THERAPEUTICS LLC·Filed 2024·Granted Dec 2, 2025·1 cites·14 claims
- 0590US11246864B2Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularizationADS THERAPEUTICS LLC·Filed 2017·Granted Feb 15, 2022·3 cites·10 claims
- 0687US12156873B2Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the sameADS THERAPEUTICS LLC·Filed 2019·Granted Dec 3, 2024·2 cites·7 claims
- 0785US12214049B2Anti-angiogenic antibody-drug conjugatesADS THERAPEUTICS LLC·Filed 2020·Granted Feb 4, 2025·1 cites·15 claims
- 0884US11166977B2Compositions for treating meibomian gland dysfunctionADS THERAPEUTICS LLC·Filed 2020·Granted Nov 9, 2021·1 cites·2 claims
- 0978US11911379B2Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularizationADS THERAPEUTICS LLC·Filed 2022·Granted Feb 27, 2024·0 cites·22 claims
- 1077US2025161300A1Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the sameADS THERAPEUTICS LLC·Filed 2024·Application pending·0 cites
- 1165US2023355594A1Topical ophthalmological compositionsADS THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 1263US2025115596A1Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoateADS THERAPEUTICS LLC·Filed 2023·Application pending·0 cites
- 1357US2023398233A1Ocular antibody-drug conjugatesADS THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 1456US2024216337A1Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugsADS THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 1554US2023210770A1Topical ophthalmological compositions and methods for treating abnormal angiogenesisADS THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ADS THERAPEUTICS LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →